Cord Blood Processing Applications
According to the U.S. Department of Health and Human Services, there are approximately four million births in the United States each year. In the past, most stem-cell-rich umbilical cords and placentas were simply discarded as medical waste. However, cord blood is increasingly being “saved” and utilized during clinical transplantation applications as a source of therapeutically beneficial hematopoietic (blood-forming) stem cells. Current research is suggesting a further role for cord blood-derived stem cells in regenerative medicine for uses beyond hematopoietic reconstitution. Recovery and storage of non-hematopoietic stem cells from cord blood for future regenerative therapies is increasingly being suggested as being of value.
While there is still much to be learned about cord blood stem cells, including our very own Multi-Lineage Progenitor Cell™ (MLPC™), more than 80 diseases and conditions have been treated with cord blood and the stem cells found within it — often as a tangible or even preferred alternative to bone marrow transplantations.
As a result, the cord blood banking industry is rapidly developing to meet the increasing need to store cryopreserved stem cells for eventual transplantation at hospitals and clinics around the world. However, few cord blood processing techniques exist that provide a consistent and sterile method for obtaining stem cells, while eliminating nearly all red blood cells.
Application of PrepaCyte for Cord Blood
The PrepaCyte®-CB Cord Blood Processing System is our first clinical grade commercial product based on BioE's PrepaCyte cell separation platform. PrepaCyte-CB is specifically designed to address a variety of cord blood processing issues such as obtaining greater cellular yields and improving labor-intensive processing methods.
For more information regarding the PrepaCyte-CB cord blood processing system visit; /Product/Product.aspx?catID=1179